CA2220538A1 - .beta.-adrenergic agonists - Google Patents

.beta.-adrenergic agonists Download PDF

Info

Publication number
CA2220538A1
CA2220538A1 CA002220538A CA2220538A CA2220538A1 CA 2220538 A1 CA2220538 A1 CA 2220538A1 CA 002220538 A CA002220538 A CA 002220538A CA 2220538 A CA2220538 A CA 2220538A CA 2220538 A1 CA2220538 A1 CA 2220538A1
Authority
CA
Canada
Prior art keywords
compound
formula
alkyl
prodrug
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002220538A
Other languages
English (en)
French (fr)
Inventor
Robert Lee Dow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002220538A priority Critical patent/CA2220538A1/en
Priority to PCT/IB1995/000342 priority patent/WO1996035670A1/en
Priority to JP8533902A priority patent/JPH11504648A/ja
Priority to EP95915993A priority patent/EP0828712A1/de
Priority to CN96105900A priority patent/CN1144801A/zh
Publication of CA2220538A1 publication Critical patent/CA2220538A1/en
Priority to FI974170A priority patent/FI974170A/fi
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002220538A 1995-05-10 1995-05-10 .beta.-adrenergic agonists Abandoned CA2220538A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002220538A CA2220538A1 (en) 1995-05-10 1995-05-10 .beta.-adrenergic agonists
PCT/IB1995/000342 WO1996035670A1 (en) 1995-05-10 1995-05-10 β-ADRENERGIC AGONISTS
JP8533902A JPH11504648A (ja) 1995-05-10 1995-05-10 β−アドレナリン作動性アゴニスト
EP95915993A EP0828712A1 (de) 1995-05-10 1995-05-10 Beta-adrenergische agonisten
CN96105900A CN1144801A (zh) 1995-05-10 1996-05-07 β-肾上腺素能兴奋剂
FI974170A FI974170A (fi) 1995-05-10 1997-11-07 B-adrenergisiä agonisteja

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002220538A CA2220538A1 (en) 1995-05-10 1995-05-10 .beta.-adrenergic agonists
PCT/IB1995/000342 WO1996035670A1 (en) 1995-05-10 1995-05-10 β-ADRENERGIC AGONISTS

Publications (1)

Publication Number Publication Date
CA2220538A1 true CA2220538A1 (en) 1996-11-14

Family

ID=25679804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002220538A Abandoned CA2220538A1 (en) 1995-05-10 1995-05-10 .beta.-adrenergic agonists

Country Status (6)

Country Link
EP (1) EP0828712A1 (de)
JP (1) JPH11504648A (de)
CN (1) CN1144801A (de)
CA (1) CA2220538A1 (de)
FI (1) FI974170A (de)
WO (1) WO1996035670A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981562A (en) * 1996-01-30 1999-11-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998021184A1 (en) 1996-11-14 1998-05-22 Pfizer Inc. Process for substituted pyridines
US6001856A (en) * 1997-06-13 1999-12-14 Pfizer Inc. β-adrenergic agonists to reduce a wasting condition
KR100335169B1 (ko) * 1997-07-03 2002-05-04 야마모토 카즈모토 포화 고리를 갖는 신규한 트리시클릭 화합물 및 이를포함하는 의약 조성물
EP0920864A1 (de) * 1997-12-03 1999-06-09 Pfizer Products Inc. Kombinationstherapie durch einen spezifischen beta-3 Agonisten und einen Appetithemmer
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
CN1430603A (zh) 2000-04-28 2003-07-16 旭化成株式会社 新型双环化合物
ES2309200T3 (es) 2001-10-25 2008-12-16 Asahi Kasei Pharma Corporation Compuesto biciclico.
BRPI0416157A (pt) * 2003-11-03 2007-01-09 Boehringer Ingelheim Int composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
JPWO2010041568A1 (ja) 2008-10-09 2012-03-08 旭化成ファーマ株式会社 インダゾール誘導体
AU2009301798B2 (en) 2008-10-09 2012-03-01 Asahi Kasei Pharma Corporation Indazole compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) * 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
EP0105053B1 (de) * 1982-10-01 1988-01-20 Merck & Co. Inc. Heterocyclische Aralkylaminoethanol-Verbindungen
GB8703007D0 (en) * 1987-02-10 1987-03-18 Glaxo Group Ltd Chemical compounds
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
NZ226991A (en) * 1987-11-27 1992-03-26 Merck & Co Inc Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
EP0677043A1 (de) * 1992-12-29 1995-10-18 Smithkline Beecham Corporation Inhibitoren der blutplättchen-aggregation
BR9406823A (pt) * 1993-06-14 1996-03-26 Pfizer Aminas secundárias e agentes anti-diabéticos e antiobesidade

Also Published As

Publication number Publication date
FI974170A0 (fi) 1997-11-07
CN1144801A (zh) 1997-03-12
EP0828712A1 (de) 1998-03-18
JPH11504648A (ja) 1999-04-27
FI974170A (fi) 1997-11-07
WO1996035670A1 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
US5977124A (en) β-adrenergic agonists
US5859044A (en) β-adrenergic agonists
US5843972A (en) Heterocyclic β-adrenergic agonists
US6706743B2 (en) β3 adrenergic receptor agonists and uses thereof
MXPA97008621A (en) Agonistasó-adrenergicos, compositions that contain and use of mis
MXPA97002601A (en) Agonistasó-adrenergicos heterocicli
CA2220538A1 (en) .beta.-adrenergic agonists
US5767133A (en) Secondary amines as antidiabetic and antiobesity agents
US5627200A (en) β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
PL196943B1 (pl) Lecznicza pochodna biarylowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
CZ458390A3 (en) Diamides of pyrimidine-4,6-dicarboxylic acid, process of their preparation and medicaments based thereon
US20080300290A1 (en) Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments
US6001856A (en) β-adrenergic agonists to reduce a wasting condition
US20050075323A1 (en) Beta3 adrenergic receptor agonists and uses thereof
US4551460A (en) Pyrido[2,1-b]quinazoline derivatives useful as agents for treatment of allergic conditions and vascular disorders involving thrombosis
AU4747599A (en) Intermediates for the preparation of beta-adrenergic agonists
JPH0314562A (ja) 新規なアルキレンジアミン誘導体およびグルタミン酸遮断剤
KR100556559B1 (ko) 2-(4-(4-(4,5-디클로로-2-메틸이미다졸-1-일)부틸)-1-피페라지닐)-5-플루오로피리미딘, 이것의 제조 방법 및 이것의치료적 용도
MXPA97005815A (es) Agonistasó-adrenergicos
US20100098629A1 (en) Novel Amides Acting on the Adenosine Receptors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead